Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-05-23FDA Approved: BUPRENORPHINE HCL AND NALOXONE HCL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for buprenorphine HCl and naloxone HCl by Amneal Pharmaceuticals LLC.
-
FDA approval · 2017-05-23FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)
The FDA approved a supplemental application for ZUBSOLV (buprenorphine hydrochloride and naloxone hydrochloride) submitted by Orexo US, Inc.…
-
FDA approval · 2017-05-23FDA Approved: BUPRENORPHINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for buprenorphine by Sun Pharmaceutical Industries, Inc., through an ANDA supplement to modify or ad…
-
FDA approval · 2017-05-23FDA Approved: BUPRENORPHINE — Supplemental Application (Rhodes Pharmaceuticals L.P.)
FDA approved a supplemental application for buprenorphine from Rhodes Pharmaceuticals L.P., indicating regulatory action on an existing prod…
-
FDA approval · 2017-05-23FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for a generic buprenorphine hydrochloride and naloxone hydrochloride dihydrate product for the t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-05-23FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
FDA approved a supplemental application for a generic Buprenorphine and Naloxone product from PAI Holdings under ANDA 204431.
-
FDA approval · 2017-05-23FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical's supplemental application for buprenorphine and naloxone, confirming continued approval/availability of thi…
-
FDA approval · 2017-05-23FDA Approved: BUPRENORPHINE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s supplemental application for buprenorphine (generic), marking regulatory approval for the gene…
-
CLINICAL_TRIALS trial_result · 2017-05-10Clinical Trial Update: Prevalence and Predictors of Prolonged Post-surgical Opioid Use: a Prospective Observational Cohort Study
This completed prospective observational cohort study examines the prevalence of prolonged post-surgical opioid use and identifies predictor…
-
CLINICAL_TRIALS withdrawal · 2017-05-04Clinical Trial Update: Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3 [Phase 2]
Phase 2 trial of buprenorphine/naloxone for heroin dependence has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-05-04Clinical Trial Update: The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects [Phase 3]
A Phase 3 clinical trial evaluating buprenorphine/naloxone buccal film to initiate treatment in individuals with opioid use disorder has bee…
-
CLINICAL_TRIALS withdrawal · 2017-05-04Clinical Trial Update: Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6 [Phase 2]
A Phase 2 trial of buprenorphine/naloxone for heroin dependence and opioid-related disorders has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-05-04Clinical Trial Update: Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2 [Phase 2]
A Phase 2 clinical trial of buprenorphine/naloxone for heroin dependence conducted by the University of Colorado, Denver was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-05-04Clinical Trial Update: Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5 [Phase 2]
A Phase 2 trial of Buprenorphine/Naloxone for heroin dependence and opioid use disorders was withdrawn.
-
CLINICAL_TRIALS trial_result · 2017-04-27Clinical Trial Update: Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia [Phase 2]
A Phase 2 trial evaluating atomoxetine as an add-on therapy for co-occurring stimulant use disorder and opioid use disorder in individuals o…
-
CLINICAL_TRIALS research · 2017-04-25Clinical Trial Update: Expanded HIV Care in Opioid Substitution Treatment (EHOST) Trial [NA]
The Expanded HIV Care in Opioid Substitution Treatment (EHOST) trial (NCT02440256) has completed, evaluating integration of HIV care within …
-
CLINICAL_TRIALS research · 2017-04-17Clinical Trial Update: Safety and Health Intervention Project [NA]
The entry notes the completion of a University of Michigan–sponsored safety and health intervention trial addressing drug overdose and opioi…
-
CLINICAL_TRIALS trial_result · 2017-04-04Clinical Trial Update: An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects [Phase 2]
An open-label Phase 2 study evaluating safety and tolerability of BEMA Buprenorphine NX in individuals with opioid use disorder has complete…
-
FDA approval · 2017-03-27FDA Approved: BUPRENORPHINE — Original Application (Rhodes Pharmaceuticals L.P.)
FDA approves Rhodes Pharmaceuticals L.P.'s original ANDA application for a generic buprenorphine product.
-
FDA approval · 2017-03-23FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental ANDA for buprenorphine and naloxone from Sun Pharmaceutical Industries, expanding access to a generic formulatio…
-
CLINICAL_TRIALS trial_result · 2017-03-22Clinical Trial Update: A Study of Breastfeeding in Buprenorphine Maintained Women
This completed study from Johns Hopkins University evaluated breastfeeding outcomes in women maintained on buprenorphine for opioid dependen…
-
FDA approval · 2017-03-10FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for methadone hydrochloride from Hikma Pharmaceuticals USA Inc., approving the generic product's sup…
-
CLINICAL_TRIALS trial_result · 2017-03-06Clinical Trial Update: Improving Delivery of Mental Health Services for Patients With Drug Use and Other Behavioral and Emotional Problems [NA]
A completed study from Johns Hopkins comparing integrated versus non-integrated psychiatric care in opioid-dependent patients on methadone w…
-
CLINICAL_TRIALS trial_result · 2017-03-03Clinical Trial Update: Buprenorphine's Dose Response Curve [Phase 2]
Phase 2 study from Johns Hopkins investigates buprenorphine's dose-response for opioid-related disorders, with results posted.
-
CLINICAL_TRIALS trial_result · 2017-03-03Clinical Trial Update: A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals [Phase 1, Phase 2]
A within-subject study evaluating opioid withdrawal in opioid-dependent individuals across Phase 1 and Phase 2, with results posted after co…